Medical data and technology company HeraMED Limited (ASX:HMD) has signed an agreement with Joondalup Health Campus (JHC) in WA, which incorporates a paid pilot of its HeraCARE solution involving 100 expectant mothers as the initial phase of an anticipated commercial roll-out for the use of HeraMED’s technology as a standard service, to be offered to all pregnant mothers under JHC’s care.
In October 2020, HeraMED announced outstanding results from a clinical study undertaken by JHC that delivered clinical and functional validation of the HeraBEAT device. The accuracy of the HeraBEAT device was found to be excellent when compared to the industry gold standard CTG (Phillips Avalon) machine. The Foetal Heart Rate (FHR) was detected on 100% of occasions by clinicians and importantly, the FHR was detected on 100% of occasions by the expectant mothers when using the device without assistance.
CEO and Co-founder,David Groberman, said the Joondalup agreement represents an important next stage of the collaboration in which JHC is undertaking to incorporate the HeraCARE platform to introduce an innovative model for remote monitoring and care management for pregnant women, allowing for the HeraBEAT device and foetal heart rate data to be used in telehealth consultations.
We are delighted to have reached this agreement with JHC as it represents a significant achievement in our commercialisation strategy,” Mr Groberman said.
“Representing the first agreement for the full blown HeraCARE platform, on a Technology as a Service basis, it is in line with our commercialisation strategy and is expected to underpin further awareness of our technology amongst global healthcare providers.
“JHC is part of Australia’s largest private hospital operator; Ramsay Health Care Group and is well regarded as an early adopter of new technologies in obstetrics.
“It is particularly pleasing that JHC have adopted HeraMED’s innovative technology as it forms part of their strategic plan to become market leaders in adopting innovative care models based on digital health, home-based remote monitoring. We are confident that this partnership will underpin further opportunities with health providers in Australia and globally,” he said.
JHC CEO, Dr Amanda Ling,said they the organisation is looking forward to being able to incorporate the HeraCARE platform into its remote monitoring and care management programmes for pregnant women.
“At JHC, we are continually evaluating and adopting new technology that will improve the patient care and this agreement is a demonstration of that strategy at work,” she said.
Mr Groberman said the HeraBEAT device forms the backbone of HeraMED’s comprehensive HeraCARE SaaS and IoT platform, a digital hybrid maternity care solution. HeraMED’s proprietary technology has already obtained TGA (Australia) and CE (Europe) approvals for OTC (over the counter) home use as well as FDA 510K clearance for home use under prescription in the US.
He said the JHC agreement represents a milestone step in HeraMED’s execution of its well-defined commercialisation strategy. HeraMED’s strategy is focused on providing access to healthcare providers across Australia and USA that have experience using remote monitoring services. The strategy focuses on obtaining clinical validation and endorsement by key opinion leaders, to support adoption of the HeraCARE platform by globally recognised healthcare providers.
Mr Groberman said the onset of COVID-19 has presented a unique opportunity globally to fast-track adoption of digital health in maternity care. HeraMED is well-placed to deliver high-quality, prenatal, and postpartum care to improve the safety, efficiency, and cost of maternal healthcare. HeraMED continues to receive significant interest from prospects from around the world and is focused on progressing the growing pipeline of potential partnerships.
